x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAA-001068
| Product Information | |
|---|---|
| Product Name | Human BDNF ELISA Kit, Fluorescent |
| Species | Human |
| Description | BDNF in vitro CatchPoint SimpleStep ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of BDNF protein in human serum, plasma, and cell culture supernatant |
| Sample Types | Cell Culture Supernatant, Serum, Hep Plasma, Edta Plasma, Cit Plasma |
| Detection Range | 2 pg/mL - 2000 pg/mL |
| Sensitivity | 1.5 pg/mL |
| Target Information | |
|---|---|
| Target Name | BDNF |
| UniProt No. | P23560 |
| Gene ID | 627 |
| Target Description | During development, promotes the survival and differentiation of selected neuronal populations of the peripheral and central nervous systems. Participates in axonal growth, pathfinding and in the modulation of dendritic growth and morphology. Major regulator of synaptic transmission and plasticity at adult synapses in many regions of the CNS. The versatility of BDNF is emphasized by its contribution to a range of adaptive neuronal responses including long-term potentiation, long-term depression, certain forms of short-term synaptic plasticity, as well as homeostatic regulation of intrinsic neuronal excitability. |
| Alternative Names | Abrineurin; ANON2; BDNF; BDNF_HUMAN; Brain Derived Neurotrophic Factor; Brain-derived neurotrophic factor; BULN2; MGC34632; Neurotrophin |
| Shipping & Storage | |
|---|---|
| Sipping | Shipping on dry ice. |
| Storage | Store at +4°C. Please refer to protocols. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
